KKR pays $5.7 billion all-cash for Integer Holdings, betting outsourced cardio scales

KKR agreed Monday to take Integer Holdings private for $5.7 billion in cash, paying $126 per share for the Plano-based medical-device contract manufacturer. The price represents a 31% premium to Friday's close. Integer shareholders receive liquidity by year-end if regulators clear the deal on schedule.

Integer is a contract development and manufacturing organization — a CDMO — serving cardiac rhythm management, neuromodulation, and vascular access markets. The firm generated roughly $1.6 billion in trailing revenue and operates 19 facilities across three continents. Its customer base includes the majors: Medtronic, Abbott, Boston Scientific. The business model is unit-economics leverage — fixed manufacturing overhead amortized across rising volumes as device utilization climbs in aging populations. Integer does not brand products; it fabricates components under long-term supply agreements with original equipment manufacturers who own the end-customer relationships.

KKR's thesis hinges on three compounding tailwinds. First, the global population aged 65-plus will expand from 761 million in 2021 to an estimated 1.6 billion by 2050, per United Nations projections. Cardiac device implant volumes track that cohort with a 0.85 correlation historically. Second, health-system consolidation has pushed device OEMs to outsource capital-intensive manufacturing to preserve balance-sheet flexibility. Integer's top-ten customers now represent 72% of revenue, up from 63% five years ago — sticky relationships that renew at multi-year intervals. Third, the private format lets management invest in automation and cleanroom capacity without quarterly-earnings scrutiny. KKR has run this playbook before: it took Envision Healthcare private in 2018 for $9.9 billion, restructured operations outside public-market glare, then harvested value through asset sales and dividend recaps.

The deal accelerates a broader private-equity pivot into healthcare infrastructure. Blackstone acquired Medline Industries for $34 billion in 2021. Carlyle took MedAssets private in 2016, then flipped pieces to firms like Avant-garde Health. The common thread is annuity-like revenue tied to non-discretionary procedure volumes. Integer's EBITDA margins hovered near 18% last quarter — middling for contract manufacturing but expandable under operational discipline. KKR will likely consolidate underutilized facilities, renegotiate supplier contracts at scale, and push automation in high-mix product lines where labor still dominates cost structure. The firm has $64 billion in dry powder across its flagship Americas and Global Impact funds, per second-quarter disclosures. It needed a sizable check to deploy; Integer fit the mandate.

Watch three follow-on events. First, antitrust clearance from the Federal Trade Commission, expected by late November if no second requests emerge. The deal faces minimal competitive overlap since KKR owns no rival CDMOs in the cardiac-device vertical. Second, potential bolt-on acquisitions once the transaction closes — smaller neuromodulation or vascular-access manufacturers that Integer can absorb into existing facilities to drive throughput. Third, refinancing activity in the $3.2 billion debt package KKR will layer onto Integer's balance sheet. Floating-rate tranches will reprice as the Federal Reserve telegraphs its terminal rate, likely in the 5.25%-to-5.50% range through mid-2025.

The premium Integer's board accepted — 31% — is tight by historical CDMO standards. Comparable take-privates in the sector have commanded 35%-to-45% premiums when strategic buyers competed. KKR faced no announced rival bidders, which suggests the board ran a narrow process or that other private-equity firms declined to underwrite the growth assumptions. Either way, the number implies confidence in operational improvement rather than multiple expansion. Integer's equity holders exit at $126. The question KKR must answer is whether it can extract $160-plus per share in value through margin enhancement and strategic repositioning before it seeks an exit, likely four to six years from close.